PTGS2 and colorectal carcinoma: We demonstrate that COX-1 and COX-2 drive EPA resistance of CRC cells and that the widely used, non-selective COX inhibitor aspirin and selective COX-2 inhibitor celecoxib mirror the effect of genetic ablation of COX-1 and COX-2 by sensitising multiple human and mouse CRC cell lines to EPA in vitro.